Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed. I see they went to hide back in the woodwork...And a 9.43 after hours close to boot. awesome!
That's the way it goes. Hard to figure the way a stock is going to move sometimes. Just goes to show you how information is leaked...Hey better late than never as the saying goes... Lots of Investors making big $$$ on this one.
Good for you. I've been in since 3.90. Hope you make some $$$
How did you make out with the big drop today? lol, Don't quit your day job.
Tomorrow this will pass $12- Once again naysayers be damned
Blasted right past 7.00 this stock is going to 10.00 plus today.
My post from yesterday early AM:
Lots of insider buying late December, early January @ 4.00. It doesn't appear anyone has sold yet also. At least according to this.
openinsider.com/screener?fd=0&fdr=&td=0&tdr=&s=PTBI&o=&t=p&minprice=&maxprice=&v=0&sicMin=&sicMax=&sortcol=0&maxresults=500
Yes I agree. Did you see the insider trading I posted in the AM. No one has sold as of yet unless they did today.
I'm going to keep flipping for profits like I always do no matter where the price range. As long as it's hot I'm buying. If not I'll hold some and move on to the next one.
I always take my profits. Tomorrow it will blast past $8.00 just like I said it would hit at least 6.50 today
So why are you here? Go create panic elsewhere.
High of 4.50 already pre-market. This will pass $5.00 easily
6.50. Hey it had a 52 week high of 26.00
Lots of insider buying late December, early January @ 4.00. It doesn't appear anyone has sold yet also. At least according to this.
http://openinsider.com/screener?fd=0&fdr=&td=0&tdr=&s=PTBI&o=&t=p&minprice=&maxprice=&v=0&sicMin=&sicMax=&sortcol=0&maxresults=500
Well excuse me.....My mistake. I corrected it I hope that makes you happy.
VLTC which Ichan bought went from .63 to a high of 21.75 (See below)in a few weeks. So why not this?
https://finance.yahoo.com/q/hp?s=VLTC+Historical+Prices
TD Ameritrade lets you trade pre-market hours starting at 8AM and after hours till 8PM. I bought some at 3.90 last evening. Scottrade starts at 7AM and there is another Broker that will let you trade at 4AM. I think you needs $25,000 Equity for the latter however.
MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies
New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer
SAN DIEGO, May 4, 2015 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced new pre-clinical data showing mitochondria-specific effects of the Company's investigational drug candidate ME-344 in cancer cells, including significantly enhanced anti-tumor activity when combined with a tyrosine-kinase inhibitor (TKI). In addition, a recently published study found ME-344 to be a potent inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) complex I, a direct molecular target.
"We continue to be very excited by the potential of this novel mitochondrial inhibitor," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "ME-344 has demonstrated broad and potent anti-tumor activity in a number of pre-clinical studies, followed by promising single-agent activity in the clinic. Now a body of data is emerging that show compelling anti-cancer effects when combining ME-344 with anti-angiogenic agents, such as TKIs, to inhibit both mitochondrial and glycolytic metabolism. These new data will help to direct future studies of ME-344 as we near completion of our Phase Ib study in small cell lung and ovarian cancers."
In a paper published in the most recent issue of American Journal of Cancer Research1, the Company's collaborators at the MIMR-PHI Institute of Medical Research in Melbourne identified mitochondrial OXPHOS complex I as a direct molecular target of ME-344, its inhibition causing an immediate reduction of mitochondrial oxygen consumption. This important finding provides new understanding of how ME-344 induces cell death by disrupting mitochondrial metabolism. A copy of the paper is available at www.meipharma.com.
To gain further insight into its mechanism of action, researchers at the Medical University of South Carolina in Charleston compared the activity of ME-344 in sensitive and naturally resistant lung cancer cell lines. In a dose dependent manner, ME-344 caused instantaneous and pronounced inhibition of oxygen consumption rates in drug-sensitive lung cancer cells, but significantly less in drug-resistant cells. Notably, drug resistance correlated with higher glycolytic metabolism in these cells.
Using a well-characterized spontaneous breast tumor model, researchers at the Spanish National Cancer Research Centre in Madrid found that chronic treatment with the small molecule TKI nintedanib (formerly BIBF 1120) significantly diminished tumor cell glycolysis, however the growing tumor shifted to reliance on mitochondrial metabolism as its primary energy source. Subsequently, tumors primed by treatment with nintedanib showed significantly enhanced sensitivity to the mitochondrial inhibitor ME-344, with synergistic anti-tumor activity.
These findings are presented in a poster, entitled "ME-344, a novel isoflavone with activity as a mitochondrial oxygenase inhibitor," which is available at www.meipharma.com. An abstract of the presentation can be found on the American Association for Cancer Research (AACR) website at aacr.org.
Results from First-in-Human Study Published in Cancer
Results from MEI Pharma's Phase I study of ME-344 were recently published in the April 1, 2015 issue of Cancer2. The study showed evidence of single-agent activity in patients with refractory solid tumors, including five patients who experienced progression-free survival that was at least twice the duration of their last prior treatment. Notably, one patient with small cell lung cancer achieved a confirmed partial response and remained on study for 104 weeks. ME-344 was generally well tolerated in the study at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue. Dose limiting toxicities were observed at both the 15 and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy.
In May 2014, the Company initiated a Phase Ib clinical trial of ME-344 in combination with topotecan (marketed as Hycamtin®), a drug approved by the U.S. Food and Drug Administration for the treatment of small cell lung, ovarian and cervical cancers. In October 2014, the first patient was dosed in the cohort-expansion stage of the study after the initial stage confirmed the maximum tolerated dose of ME-344 at 10 mg/kg in combination with 4 mg/m2 of topotecan. The combination of ME-344 and topotecan has been generally well tolerated in the study; the most frequent side effects are fatigue and gastrointestinal disturbances. The study is currently enrolling an additional 40 patients into two cohorts, locally advanced or metastatic small cell lung and ovarian cancer, at nine sites in the U.S. and U.K. The Company expects to present data from the ovarian cancer cohort at a scientific meeting during the fourth quarter of 2015.
MEI Pharma owns exclusive worldwide rights to all of its drug candidates, including ME-344.
Yes I think I just jump-started it. lol
Too bad it's not going. Seems like nobody cares. Can't figure this stock out.
Anthera Pharmaceuticals Receives “Buy” Rating from Zacks (ANTH)
Anthera Pharmaceuticals logoAnthera Pharmaceuticals (NASDAQ:ANTH)‘s stock had its “buy” rating reissued by Zacks in a report issued on Friday. They currently have a $5.75 price target on the stock. Zacks‘s price objective would indicate a potential upside of 26.37% from the stock’s previous close.
Zacks’ analyst wrote, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjogren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
A number of other analysts have also recently weighed in on ANTH. Analysts at Piper Jaffray raised their price target on shares of Anthera Pharmaceuticals to $7.50 in a research note on Monday, March 30th. Separately, analysts at Jefferies Group reiterated a “buy” rating and set a $12.00 price target (down previously from $18.00) on shares of Anthera Pharmaceuticals in a research note on Tuesday, March 17th.
Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 6.06% during mid-day trading on Friday, hitting $4.55. The stock had a trading volume of 275,372 shares. Anthera Pharmaceuticals has a 52 week low of $1.46 and a 52 week high of $6.37. The stock’s 50-day moving average is $4. and its 200-day moving average is $3.. The company’s market cap is $132.36 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings data on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. Analysts expect that Anthera Pharmaceuticals will post $-1.17 EPS for the current fiscal year.
Yes she did. Like I said it has been known to pop here and there and without any news.
I bought this for just over a dollar a year ago. It has had some good momo lately including hitting a high of 6.50 not too long ago so you never know. I think it's a safe buy at these levels.
Maybe in Fantasyland. Not on this planet.
http://www.biopharmcatalyst.com/clinical-database/
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy
http://investor.anthera.com/releasedetail.cfm?ReleaseID=901728
Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
Anthera to Form a New Subsidiary, Alkira Therapeutics, to Assume All Development Activities and Registration Activities as a Subsidiary of Anthera
http://investor.anthera.com/releasedetail.cfm?ReleaseID=859598
Anthera Pharmaceuticals Reports 2014 Fourth Quarter and Fiscal Year Financial Results, Operational Update and Recent Event Highlights
- CHABLIS-SC enrollment on track for completion in mid-2015, interim analysis completed
- Blisibimod autoimmune programs partnered with Zenyaku Kogyo Co., Ltd, Tokyo, Japan
- Sollpura (liprotamase) manufacturing agreement executed with Patheon for clinical product supply
- Eliminated all long-term debt
http://investor.anthera.com/releasedetail.cfm?ReleaseID=901716
Novogen Completes the Private Placement of Equity
http://finance.yahoo.com/news/novogen-completes-private-placement-equity-073200143.html
SYDNEY, April 29, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (NRT: ASX; NVGN: NASDAQ) (Novogen or Company), announced today that it has completed the placement to US institutional investors of 51,750,000 ordinary shares, raising a total of $15,525,000 (before costs), as previously announced to the market on 21 April 2015.
Subject to Shareholder approval, the Company will issue 51,750,000 unlisted options exercisable at $0.30 within 6 months from the date of issue and 25,875,000 unlisted options exercisable at $0.40 within 5 years from the date of issue.
Dr Graham Kelly, Novogen group CEO and Executive Chairman, said, "This is the first of a three-step process that has been designed to deliver the financial security that the Company needs to commit to a substantial growth strategy. The second step will see the Company complete a pro-rata, non-renounceable Rights Issue offering in early June, which the Company believes will be fully subscribed, bringing its cash position mid-year to about $44M."
"The third step involves the tranche of options with a 6-month exercise term, that are intended to take advantage of current strong market sentiment for the biotech sector, along with an anticipated strong news flow over the remainder of this year following the ramping up of the Company's broad R&D programs."
"We now have certainty and the means to grow into the extraordinary opportunity that our two drug technology platforms have presented us with," Kelly said.
The funds will be applied to bringing a pipeline of 3 oncology drugs (Cantrixil, Trilexium, Anisina) through the clinic to the point intended to test their ability to provide a meaningful clinical benefit to patients with abdominal cancers (malignant ascites), adult and paediatric brain cancers, neuroblastoma, malignant melanoma and castrate-resistant prostate cancer. In the non-oncology space, the programs of ulcerative colitis, repair of brain and spinal injury, the treatment of muscular dystrophies, and the treatment of lysosomal storage diseases, will all now be moved into active phases with the intention of identifying at least 3 candidate drugs to be made clinic-ready within 2 years.
Plenty of opportunities for buying here because this POS is never going anywhere. Don't get stuck holding this bag
Sheff posted that he has re-entered MEIP. When Sheff buys Investors usually pay attention. He has an unbelievable track record for those who do not know him.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113145599
Novogen Regains Full Compliance with NASDAQ Listing Rule
SYDNEY, April 28, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) (Company), announced today that it received a letter from NASDAQ informing it that it had regained full compliance with NASDAQ Listing Rule 5550(b) (Listing Rule).
In November 2014, the Company received a deficiency notice from NASDAQ, requesting the Company to submit a plan to regain compliance with the Listing Rule, which requires either (i) a minimum of $2,500,000 in stockholders' equity as of June 30, 2014; (ii) at least $35,000,000 market value of listed securities, or (iii) at least $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years.
Further to lodgement of its plan to regain compliance, NASDAQ granted an extension to the Company in January 2015.
The recent growth in the Company's market value, as well as the substantial increase of its assets with the current capital-raising program, has allowed the Company to regain compliance with the Listing Rule.
Graham Kelly, Novogen Group CEO and Executive Chairman, said, "Novogen regards itself as a joint US-Australian company. Roughly half of our shareholders are US residents. We have a joint venture company with one of the leading universities in the US. We are conducting increasing collaborations with leading US research institutions and hospitals as our drug technologies get better appreciated. The US eventually will be the leading market for our drug candidates. Maintaining our NASDAQ listing is vital to us."
Conatus Pharmaceuticals Now Covered by Brean Capital (CNAT)
Research analysts at Brean Capital assumed coverage on shares of Conatus Pharmaceuticals (NASDAQ:CNAT) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a research note on Tuesday, March 17th. They set a “buy” rating and a $15.00 price target on the stock. Analysts at Stifel Nicolaus lowered their price target on shares of Conatus Pharmaceuticals from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, March 12th. Finally, analysts at MLV & Co. set a $16.00 price target on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, March 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $12.13.
http://tickerreport.com/banking-finance/476051/conatus-pharmaceuticals-now-covered-by-brean-capital-cnat/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN
Amended Statement of Changes in Beneficial Ownership (4/a)
Date : 04/27/2015 @ 2:41PM
Source : Edgar (US Regulatory)
Stock : Carbylan Therapeutics, Inc. (MM) (CBYL)
Quote : 6.95 -0.5 (-6.71%) @ 3:03PM
http://ih.advfn.com/p.php?pid=nmona&article=66590615&symbol=CBYL
AKBA, CBYL, CBMX all heavy recent insider buying
Carbylan Therapeutics, Inc. (CBYL)
Clinical Studies
Our Phase 2b clinical trial of Hydros-TA, known as COR1.0, was a prospective, multicenter, randomized, double-blind feasibility study to evaluate the safety and performance of Hydros-TA in subjects with OA of the knee. Eight clinical centers in Canada, Europe and the Caribbean participated in the COR1.0 trial. A total of 98 subjects were enrolled, treated and followed for six months post-treatment. Subjects were randomized 1:1:1 to receive a single 6mL intra-articular injection of one of three study treatments: Hydros- TA, Hydros (the viscosupplement without steroid) and Synvisc-One (the U.S. market leading HA viscosupplement).
Key Observations from COR1.0: The results from COR1.0 suggest that a single injection of Hydros-TA was well-tolerated and could relieve pain associated with symptomatic OA of the knee over 26 weeks. Although not statistically significant, Hydros-TA demonstrated a numerically higher pain relief at all time points after injection when compared with Synvisc-One and the percentage of subjects who responded favorably to the product as measured by the OMERACT-OARSI responder rate was higher in the Hydros and Hydros-TA groups when compared to Synvisc-One.
To our knowledge, this is the first clinical study to report on the safety and effectiveness of a single-injection viscosupplement that combines HA and corticosteroid for the treatment of knee OA. Reductions in WOMAC pain scores observed in this study suggest that this combination may have a faster onset of pain relief compared to non-steroid containing products and may provide improved pain relief over the full 26 weeks post injection. These results reflect a synergistic effect of combining HA with a corticosteroid.
Phase 3 Clinical Trial Program
The first of our two pivotal Phase 3 trials began enrollment in mid-January 2014. We are actively enrolling up to 510 subjects at 30 to 40 sites in Australia, Canada, New Zealand, Europe and the Caribbean.
Carbylan Therapeutics Inc (CBYL): Broadfin’s Latest Move and Market Smashing Q1 Returns Inside
http://www.insidermonkey.com/blog/carbylan-therapeutics-inc-cbyl-broadfins-latest-move-and-market-smashing-q1-returns-inside-343147/
Statement of Beneficial Ownership (sc 13d)
http://ih.advfn.com/p.php?pid=nmona&article=66556500&symbol=CBYL
Lots of Insider Trading on this stock.
http://www.insider-monitor.com/top10_insider_buys_week.html
Some pre-market action
http://www.nasdaq.com/symbol/athx/premarket
@Investor666
$ATHX-Athersys to Host Shareholder Conference Call - http://NASDAQ.com http://www.nasdaq.com/press-release/athersys-to-host-shareholder-conference-call-20150424-00161 …
Indeed. Should past 9.00 easily today.
AKB-6548:Phase 2a enrollment completed March 2015. Data due 3rd Quarter 2015, Phase 3 planned 2015
http://www.biopharmcatalyst.com/clinical-database/